Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
May 02 04:00PM ET
0.3687
Dollar change
-0.0113
Percentage change
-2.97
%
Index- P/E- EPS (ttm)-1.60 Insider Own40.16% Shs Outstand45.70M Perf Week32.29%
Market Cap16.87M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float27.38M Perf Month8.09%
Income-71.06M PEG- EPS next Q- Inst Own8.63% Short Float0.60% Perf Quarter-19.45%
Sales2.56M P/S6.59 EPS this Y- Inst Trans-4.73% Short Ratio1.40 Perf Half Y31.77%
Book/sh1.46 P/B0.25 EPS next Y- ROA-61.76% Short Interest0.17M Perf Year-62.76%
Cash/sh0.79 P/C0.47 EPS next 5Y- ROE-95.50% 52W Range0.27 - 1.10 Perf YTD-44.14%
Dividend Est.- P/FCF- EPS past 5Y- ROI-70.74% 52W High-66.48% Beta2.89
Dividend TTM- Quick Ratio5.62 Sales past 5Y7.49% Gross Margin-111.99% 52W Low36.50% ATR (14)0.04
Dividend Ex-Date- Current Ratio5.62 EPS Y/Y TTM5.91% Oper. Margin-2970.75% RSI (14)55.56 Volatility16.45% 11.52%
Employees48 Debt/Eq0.56 Sales Y/Y TTM-19.54% Profit Margin-2774.62% Recom3.00 Target Price2.00
Option/ShortNo / Yes LT Debt/Eq0.50 EPS Q/Q-0.87% Payout- Rel Volume0.82 Prev Close0.38
Sales Surprise- EPS Surprise- Sales Q/Q-100.00% EarningsMar 21 AMC Avg Volume118.20K Price0.37
SMA2013.14% SMA50-1.24% SMA200-23.14% Trades Volume99,519 Change-2.97%
Date Action Analyst Rating Change Price Target Change
Oct-07-22Initiated Morgan Stanley Equal-Weight $7.50
Apr-30-24 08:05AM
Mar-21-24 10:53PM
04:05PM
Jan-05-24 04:05PM
Dec-26-23 11:32AM
12:12PM Loading…
Dec-22-23 12:12PM
06:30AM
Nov-13-23 04:15PM
Nov-07-23 07:54AM
Nov-06-23 04:05PM
Oct-31-23 09:06AM
Sep-27-23 09:05AM
Sep-26-23 04:05PM
Sep-05-23 08:30AM
Aug-11-23 09:50AM
08:35AM Loading…
08:35AM
Aug-10-23 08:35AM
Jun-05-23 08:04AM
May-20-23 08:05AM
May-09-23 04:05PM
May-02-23 04:45PM
Apr-17-23 08:45AM
Apr-14-23 09:00AM
Mar-22-23 05:09PM
Mar-14-23 04:35PM
Feb-06-23 06:26AM
Feb-03-23 04:05PM
Feb-01-23 04:05PM
Jan-27-23 08:00AM
Dec-27-22 06:53AM
07:55AM Loading…
Dec-19-22 07:55AM
Dec-11-22 09:00AM
Nov-23-22 07:55AM
Nov-16-22 06:16AM
Nov-10-22 07:55AM
Nov-03-22 09:05AM
Oct-28-22 04:05PM
Oct-05-22 08:01AM
Oct-04-22 07:04AM
Sep-20-22 04:02PM
Sep-06-22 04:01PM
Sep-01-22 11:57AM
Aug-19-22 04:05PM
Aug-15-22 04:05PM
Jul-30-22 09:13AM
Jul-01-22 10:39AM
Jun-13-22 12:55PM
Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.